Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effects of Autologous Conditioned Serum on Non-Union After Open Reduction Internal Fixation Failure: A Case Series and Literature Review.
Medicina (Kaunas)
November 2024
Department of Orthopedics, Cheng-Ching General Hospital, Taichung 40764, Taiwan.
Article Synopsis
- - Non-union is a serious complication of traumatic fractures that can result in long-term disability; this study explores the treatment of non-union with autologous conditioned serum (ACS) in patients who had unsuccessful open reduction internal fixation (ORIF).
- - The study involved 11 patients with non-union who received ACS therapy on their injury sites at varying frequencies, with progress monitored through monthly X-rays for signs of bone healing.
- - Out of the 11 participants, 10 successfully achieved bone union, suggesting that ACS may be an effective alternative treatment for non-unions not responsive to traditional surgical methods, and further research is warranted to examine its benefits.
The COVID-19 pandemic introduced new landscapes for research and public engagement participation. This shift was accompanied by significant challenges and unique opportunities for engaging youth as active participants and collaborators. This commentary will reflect on insights gained from conducting a variety of virtual youth engagement activities during the pandemic, within a rights-based and empirical approach.
View Article and Find Full Text PDFMolecular tumor board in patients with metastatic breast cancer.
Breast Cancer Res Treat
October 2024
Division of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Via G. Ripamonti 435, 20141, Milan, Italy.
Purpose: Comprehensive genomic profiling is becoming increasingly important in the management of patients with metastatic breast cancer (mBC). Real-world clinical outcomes from applying molecular tumor boards (MTBs) recommendations in this context remain limited. Accordingly, we conducted a retrospective, single-institution analysis to evaluate the clinical impact of discussing patients affected by mBC at the MTB.
View Article and Find Full Text PDFPhase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C.
Clin Cancer Res
January 2025
Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
Purpose: Amplification of cyclin-dependent kinase 4 (CDK4) and CDK6 is a feature of a variety of malignancies, and preclinical evidence suggests that inhibition of CDK4/6 is a plausible treatment strategy in these tumors. Subprotocol Z1C of the NCI-Molecular Analysis for Therapy Choice trial was designed to evaluate the CDK4/6 inhibitor palbociclib in CDK4- or CDK6-amplified tumors.
Patients And Methods: Patients had a solid malignancy or lymphoma with progression on at least one systemic therapy for advanced disease or with no standard-of-care therapy available.
Clinical efficacy analysis of endoscopic band electrocision ligation surgical method in the treatment of small submucosal tumors of the gastric fundus.
Minim Invasive Ther Allied Technol
December 2024
Department of Pathology, The Affiliated Hexian Memorial Hospital of Southern Medical University, Guangzhou, China.
Article Synopsis
- This study aimed to compare the effectiveness of two techniques, endoscopic submucosal dissection (ESD) and endoscopic band electrocision ligation (EEL), for removing small gastric submucosal tumors (SMTs).
- It analyzed data from 130 patients, revealing that EEL resulted in significantly shorter surgery times, lower costs, and less blood loss compared to ESD, with no major differences in hospital stays or complications afterward.
- Ultimately, the study concluded that EEL is a more efficient and cost-effective method for treating SMTs under 10 mm than ESD, making it a valuable option in clinical settings.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!